Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.
2.

A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.

Joshi J, Malla N, Kaur S.

Parasitol Int. 2014 Aug;63(4):612-20. doi: 10.1016/j.parint.2014.04.002. Epub 2014 Apr 18.

PMID:
24747611
3.
4.

Asparagus racemosus ameliorates cisplatin induced toxicities and augments its antileishmanial activity by immunomodulation in vivo.

Sachdeva H, Sehgal R, Kaur S.

Parasitol Int. 2014 Feb;63(1):21-30. doi: 10.1016/j.parint.2013.09.016. Epub 2013 Oct 6.

PMID:
24103199
5.

Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.

Islamuddin M, Chouhan G, Want MY, Ozbak HA, Hemeg HA, Afrin F.

PLoS Negl Trop Dis. 2016 Oct 24;10(10):e0005011. doi: 10.1371/journal.pntd.0005011. eCollection 2016 Oct.

6.

Studies on the protective and immunomodulatory efficacy of Withania somnifera along with cisplatin against experimental visceral leishmaniasis.

Sachdeva H, Sehgal R, Kaur S.

Parasitol Res. 2013 Jun;112(6):2269-80. doi: 10.1007/s00436-013-3387-2. Epub 2013 Mar 22.

PMID:
23519426
7.

Antileishmanial effect of cisplatin against murine visceral leishmaniasis.

Kaur S, Sachdeva H, Dhuria S, Sharma M, Kaur T.

Parasitol Int. 2010 Mar;59(1):62-9. doi: 10.1016/j.parint.2009.10.006. Epub 2009 Oct 21.

PMID:
19853668
8.

Tinospora cordifolia as a protective and immunomodulatory agent in combination with cisplatin against murine visceral leishmaniasis.

Sachdeva H, Sehgal R, Kaur S.

Exp Parasitol. 2014 Feb;137:53-65. doi: 10.1016/j.exppara.2013.12.006. Epub 2013 Dec 25.

PMID:
24370645
9.

Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.

Shakya N, Sane SA, Vishwakarma P, Bajpai P, Gupta S.

Acta Trop. 2011 Aug;119(2-3):188-93. doi: 10.1016/j.actatropica.2011.05.017. Epub 2011 Jun 7.

PMID:
21679679
10.

Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.

Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.

MBio. 2013 Oct 8;4(5):e00611-13. doi: 10.1128/mBio.00611-13.

11.

Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.

Asad M, Bhattacharya P, Banerjee A, Ali N.

BMC Infect Dis. 2015 Apr 17;15:188. doi: 10.1186/s12879-015-0928-6.

12.

Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Kaur T, Makkar P, Randhawa K, Kaur S.

Parasitol Res. 2013 Jan;112(1):91-100. doi: 10.1007/s00436-012-3108-2. Epub 2012 Sep 9.

PMID:
22961311
13.

Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis.

Islamuddin M, Chouhan G, Farooque A, Dwarakanath BS, Sahal D, Afrin F.

PLoS Negl Trop Dis. 2015 Jan 8;9(1):e3321. doi: 10.1371/journal.pntd.0003321. eCollection 2015 Jan.

14.

Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.

Bhaumik SK, Paul J, Naskar K, Karmakar S, De T.

J Antimicrob Chemother. 2012 Apr;67(4):910-20. doi: 10.1093/jac/dkr575. Epub 2012 Jan 18.

PMID:
22258930
15.

Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.

Tiwananthagorn S, Iwabuchi K, Ato M, Sakurai T, Kato H, Katakura K.

PLoS Negl Trop Dis. 2012;6(8):e1798. doi: 10.1371/journal.pntd.0001798. Epub 2012 Aug 21.

16.

Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.

Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR.

J Antimicrob Chemother. 2009 Feb;63(2):365-8. doi: 10.1093/jac/dkn509. Epub 2008 Dec 17.

PMID:
19095684
17.

Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis.

Sharma M, Sehgal R, Kaur S.

PLoS Negl Trop Dis. 2012;6(5):e1629. doi: 10.1371/journal.pntd.0001629. Epub 2012 May 1.

18.

Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.

Roychoudhury J, Sinha R, Ali N.

PLoS One. 2011 Mar 10;6(3):e17376. doi: 10.1371/journal.pone.0017376.

19.

Mycobacterium indicus pranii (Mw) re-establishes host protective immune response in Leishmania donovani infected macrophages: critical role of IL-12.

Adhikari A, Gupta G, Majumder S, Banerjee S, Bhattacharjee S, Bhattacharya P, Kumari S, Haldar S, Majumdar SB, Saha B, Majumdar S.

PLoS One. 2012;7(7):e40265. doi: 10.1371/journal.pone.0040265. Epub 2012 Jul 5.

20.

Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.

Shakya N, Sane SA, Gupta S.

Parasitol Res. 2011 Apr;108(4):793-800. doi: 10.1007/s00436-010-2230-2. Epub 2011 Jan 7.

PMID:
21212980

Supplemental Content

Support Center